Idelalisib is a targeted therapy known as a kinase inhibitor. It works by blocking a specific enzyme called PI3Kδ (phosphatidylinositol 3-kinase delta), which is found in normal and malignant B-cells. By inhibiting this enzyme, idelalisib interferes with several cell signaling pathways that are important for the survival, growth, and movement of B-cells, including those involved in B-cell receptor signaling and the movement of B-cells to lymph nodes and bone marrow.

This action leads to the death (apoptosis) of cancerous B-cells and stops their proliferation. In clinical studies, idelalisib has been shown to reduce the viability of lymphoma cells and inhibit their ability to migrate and adhere to other tissues. This makes it effective in treating certain blood cancers, particularly when other treatments have not worked or are not suitable.

idelalisib

Common brand names

Approved use in